|Articles|November 30, 2012

New Approaches to Measuring Value in Oncology Therapy
Volume 18
Issue 11 Suppl

Appendix B -- Value of Survival Gains in Chronic Myeloid Leukemia

Articles in this issue

over 13 years ago

Article

eAppendix -- New Approaches to Measuring Value in Oncology Therapy

over 13 years ago

Article

Appendix A -- Value of Survival Gains in Chronic Myeloid Leukemia

over 13 years ago

Article

Participating Faculty: New Approaches to Measuring Value in Oncology Therapy

over 13 years ago

Article

Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia

over 13 years ago

Article

Dynamic Cost-Effectiveness of Oncology Drugs

over 13 years ago

Article

The Option Value of Innovative Treatments in the Context of Chronic Myeloid Leukemia

over 13 years ago

Article

Value of Survival Gains in Chronic Myeloid Leukemia

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Appendix B -- Value of Survival Gains in Chronic Myeloid Leukemia

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis

Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care

Sarcoma Gene Signature May Predict Who Benefits From Pazopanib

Lifestyle Factors Offer Actionable Targets in MASLD Management: Zobair M. Younossi, MD